Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Clinical trial NCT02611908 · WITHDRAWN
Trial details
- NCT number
- NCT02611908
- Sponsor
- Michael Choi
- Status
- WITHDRAWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-01
- Primary completion
- 2019-11-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.